BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 30626409)

  • 21. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
    Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
    J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of intramuscular administration of scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Zhou J; Yang J; Zhu X; Zghoul T; Feng L; Chen R; Wang G
    Ther Adv Psychopharmacol; 2020; 10():2045125320938556. PubMed ID: 32655854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, double-blind, 6-week prospective pilot study on the efficacy and safety of dose escalation in non-remitters in comparison to those of the standard dose of escitalopram for major depressive disorder.
    Kim EY; Kim SH; Lee HJ; Lee NY; Kim HY; Park CHK; Ahn YM
    J Affect Disord; 2019 Dec; 259():91-97. PubMed ID: 31445345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
    Brown ES; Howard C; Khan DA; Carmody TJ
    Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does negative affectivity predict differential response to an SSRI versus a non-SSRI antidepressant?
    Gerra ML; Marchesi C; Amat JA; Blier P; Hellerstein DJ; Stewart JW
    J Clin Psychiatry; 2014 Sep; 75(9):e939-44. PubMed ID: 25295437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder.
    Leuchter AF; Lesser IM; Trivedi MH; Rush AJ; Morris DW; Warden D; Fava M; Wisniewski SR; Luther JF; Perales M; Gaynes BN; Stewart JW
    J Psychiatr Pract; 2008 Sep; 14(5):271-80. PubMed ID: 18832958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of bupropion hydrochloride extended-release versus escitalopram oxalate in Chinese patients with major depressive disorder: Results from a randomized, double-blind, non-inferiority trial.
    Shen Y; Zhao Q; Yu Y; Tan Y; Zhang H; Xu X; Wang Z; Li Y; Hu J; Zhong J; Li H
    J Affect Disord; 2019 Oct; 257():143-149. PubMed ID: 31301615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study.
    Mischoulon D; Shelton RC; Baer L; Bobo WV; Curren L; Fava M; Papakostas GI
    J Clin Psychiatry; 2017 Apr; 78(4):449-455. PubMed ID: 27835715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Randomized Double-Blind Placebo-Controlled Trial of Combined Escitalopram and Memantine for Older Adults With Major Depression and Subjective Memory Complaints.
    Lavretsky H; Laird KT; Krause-Sorio B; Heimberg BF; Yeargin J; Grzenda A; Wu P; Thana-Udom K; Ercoli LM; Siddarth P
    Am J Geriatr Psychiatry; 2020 Feb; 28(2):178-190. PubMed ID: 31519517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
    J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L; Andersen HF; Reines EH
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repurposing of dextromethorphan as an adjunct therapy in patients with major depressive disorder: a randomised, group sequential adaptive design, controlled clinical trial protocol.
    Maji S; Mohapatra D; Jena M; Srinivasan A; Maiti R
    BMJ Open; 2024 Apr; 14(4):e080500. PubMed ID: 38688675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
    Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
    Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
    J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
    Waugh J; Goa KL
    CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medication augmentation after the failure of SSRIs for depression.
    Trivedi MH; Fava M; Wisniewski SR; Thase ME; Quitkin F; Warden D; Ritz L; Nierenberg AA; Lebowitz BD; Biggs MM; Luther JF; Shores-Wilson K; Rush AJ;
    N Engl J Med; 2006 Mar; 354(12):1243-52. PubMed ID: 16554526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.